Antibiotic combinations for controlling colistin-resistant Enterobacter cloacae

Journal of Antibiotics

Volumn 70, Issue 2, 2017, Pages 122-129

  Lima, Thais Bergamin ^a,b   Silva, Osmar Nascimento ^c   De Almeida, Keyla Caroline ^a,d   Ribeiro, Suzana Meira ^c   Motta, Dielle De Oliveira ^a   Maria Neto, Simone ^a   Lara, Michelle Brizolla ^a   Filho, Carlos Roberto Souza ^a   Ombredane, Alicia Simalie ^a   De Faria Junior, Celio ^e   Parachin, Nadia Skorupa ^a   Magalhães, Beatriz Simas ^a   Franco, Octávio Luiz ^a,c,d  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^b Centro Universitário do Distrito Federal UDF SEP SUL EQ 704 904 CONJ A   (Brazil)

^c UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

^d UNIVERSITY OF BRASILIA   (Brazil)

^e Laboratório Central de Saúde Pública do Distrito Federal LACEN DF   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN; CHLORAMPHENICOL; COLISTIN; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; CROSS RESISTANCE; DNA SYNTHESIS; ENTEROBACTER CLOACAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS; CELL WALL; DRUG EFFECT; GENE EXPRESSION REGULATION; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; CELL WALL; COLISTIN; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER CLOACAE; GENE EXPRESSION REGULATION, BACTERIAL; RNA, BACTERIAL;

EID: 85010912638     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2016.77     Document Type: Article

References (48)

1. He, G. X., et al. EmmdR, a new member of the MATE family of multidrug transporters, extrudes quinolones from Enterobacter cloacae. Arch. Microbiol. 193, 759-765 (2011).
2. Yang, F. C., Yan, J. J., Hung, K. H., Wu, J. J. Characterization of ertapenem-resistant Enterobacter cloacae in a Taiwanese university hospital. J. Clin. Microbiol. 50, 223-226 (2012).
3. Heller, I., Grif, K., Orth, D. Emergence of VIM-1-carbapenemase-producing Enterobacter cloacae in Tyrol, Austria. J. Med. Microbiol. 61, 567-571 (2012).
4. Panopoulou, M., et al. Emergence of VIM-12 in Enterobacter cloacae. J. Clin. Microbiol. 48, 3414-3415 (2010).
5. Hornsey, M., et al. Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. Int. J. Antimicrob. Agents 35, 478-481 (2010).
6. Nigro, S. J., Hall, R. M. GIsul2, a genomic island carrying the sul2 sulphonamide resistance gene, the small mobile element CR2 found in the Enterobacter cloacae subspecies cloacae type strain ATCC 13047 from 1890, Shigella flexneri ATCC 700930 from 1954, Acinetobacter baumannii ATCC 17978 from 1951. J. Antimicrob. Chemother. 66, 2175-2176 (2011).
7. Coates, A. R., Halls, G. Antibiotics in phase II, III clinical trials. Handb. Exp. Pharmacol. 211, 167-183 (2012).
8. Zucca, M., Scutera, S., Savoia, D. New antimicrobial frontiers. Mini. Rev. Med. Chem. 11, 888-900 (2011).
9. Moffatt, J. H., et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54, 4971-4977 (2010).
10. Gupta, S., et al. Colistin, polymyxin B: a re-emergence. Indian J. Crit. Care Med. 13, 49-53 (2009).
11. Srivastava, S., Ghosh, J. K. Introduction of a lysine residue promotes aggregation of temporin L in lipopolysaccharides, augmentation of its antiendotoxin property. Antimicrob. Agents Chemother. 57, 2457-2466 (2013).
12. David, S. A. Antimicrobial peptides for gram-negative sepsis: a case for the polymyxins. Front. Immunol. 3, 252 (2012).
13. Lin, X. M., Yang, J. N., Peng, X. X., Li, H. A novel negative regulation mechanism of bacterial outer membrane proteins in response to antibiotic resistance. J. Proteome. Res. 9, 5952-5959 (2010).
14. Shlaes, D. M. New beta-lactam-beta-lactamase inhibitor combinations in clinical development. Ann. N. Y. Acad. Sci. 1277, 105-114 (2013).
15. Naghmouchi, K., et al. Synergistic effect between colistin, bacteriocins in controlling gram-negative pathogens, their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob. Agents Chemother. 57, 2719-2725 (2013).
16. Wallace, S. J., Nation, R. L., Li, J., Boyd, B. J. Physicochemical aspects of the coformulation of colistin, azithromycin using liposomes for combination antibiotic therapies. J. Pharm. Sci. 102, 1578-1587 (2013).
17. Kasiakou, S. K., et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob. Agents Chemother. 49, 3136-3146 (2005).
18. Olofsson, S. K., Cars, O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin. Infect. Dis. 45(suppl 2): S129-S136 (2007).
19. Pomales-Lebron, A., Fernandez, C. A method for estimating the number of bacteria in liquids, tissues. J. Bacteriol. 64, 837-845 (1952).
20. CLSI. in Approved Standard-8th ed. CLSI document M07-A8 (Clinical, Laboratory Standards Institute, Wayne, PA, 2009).
21. Peng, X., et al. Proteomic analysis of the sarcosine-insoluble outer membrane fraction of Pseudomonas aeruginosa responding to ampicilin, kanamycin, , tetracycline resistance. J. Proteome. Res. 4, 2257-2265 (2005).
22. Calderaro, A., et al. Identification of Borrelia species after creation of an in-house MALDI-TOF MS database. PLoS One. 9, e88895 (2014).
23. Mellmann, A., et al. High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. J. Clin. Microbiol. 47, 3732-3734 (2009).
24. CLSI. in Twentieth Informational Supplement. CLSI document M100-S20 (Clinical, Laboratory Standards Institute, Wayne, PA, 2010).
25. Gordon, N. C., Png, K., Wareham, D. W. Potent synergy, sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 5316-5322 (2010).
26. Lopez-Abarrategui, C., et al. Functional characterization of a synthetic hydrophilic antifungal peptide derived from the marine snail Cenchritis muricatus. Biochimie 94, 968-974 (2012).
27. Silva, O. N., et al. Cn-AMP1: a new promiscuous peptide with potential for microbial infections treatment. Biopolymers 98, 322-331 (2012).
28. Pasupuleti, M., Schmidtchen, A., Chalupka, A., Ringstad, L., Malmsten, M. End-tagging of ultra-short antimicrobial peptides by W/F stretches to facilitate bacterial killing. PLoS ONE 4, e5285 (2009).
29. Josten, M., et al. Analysis of the matrix-assisted laser desorption ionization-time of flight mass spectrum of staphylococcus aureus identifies mutations that allow differentiation of the main clonal lineages. J. Clin. Microbiol. 51, 1809-1817 (2013).
30. Kremer, A., Hoffmann, H. Prevalences of the Enterobacter cloacae complex, its phylogenetic derivatives in the nosocomial environment. Eur. J. Clin. Microbiol. Infect. Dis. 31, 2951-2955 (2012).
31. Paauw, A., et al. Genomic diversity within the Enterobacter cloacae complex. PLoS ONE 3, e3018 (2008).
32. Risch, M., et al. Comparison of MALDI TOF with conventional identification of clinically relevant bacteria. Swiss Med. Wkly. 140, w13095 (2010).
33. Munoz Bellido, J. L., Vega Castano, S., Ferreira, L., Sanchez Juanes, F., Gonzalez Buitrago, J. M. Proteomic applications in the clinical microbiology laboratory. Enferm. Infecc. Microbiol. Clin. 30, 383-393 (2012).
34. Mezzatesta, M. L., Gona, F., Stefani, S. Enterobacter cloacae complex: clinical impact, emerging antibiotic resistance. Future Microbiol. 7, 887-902 (2012).
35. Wybo, I., et al. Differentiation of cfiA-negative, cfiA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 49, 1961-1964 (2011).
36. Wolters, M., et al. MALDI-TOF MS fingerprinting allows for discrimination of major methicillin-resistant Staphylococcus aureus lineages. Int. J. Med. Microbiol. 301, 64-68 (2011).
37. Muroi, M., Shima, K., Igarashi, M., Nakagawa, Y., Tanamoto, K. Application of matrix-assisted laser desorption ionization-time of flight mass spectrometry for discrimination of laboratory-derived antibiotic-resistant bacteria. Biol. Pharm. Bull. 35, 1841-1845 (2012).
38. Malakhova, M. V., et al. MALDI-ToF mass-spectrometry in analysis of genetically determined resistance of Streptococcus pneumoniae to fluoroquinolones. Antibiot. Khimioter. 52, 10-17 (2007).
39. Hilty, M., et al. Characterisation, clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy Int. J. Antimicrob. Agents 41, 236-249 (2013).
40. Saugar, J. M., et al. Activity of cecropin A-melittin hybrid peptides against colistinresistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob. Agents Chemother. 50, 1251-1256 (2006).
41. Vidaillac, C., Benichou, L., Duval, R. E. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, , Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 56, 4856-4861 (2012).
42. Phee, L. M., et al. Colistin, fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob. Agents Chemother. 59, 4544-4550 (2015).
43. Mimoz, O., et al. Cefepime, amikacin synergy in vitro, in vivo against a ceftazidime-resistant strain of Enterobacter cloacae. J. Antimicrob. Chemother. 41, 367-372 (1998).
44. Jung, R., Husain, M., Choi, M. K., Fish, D. N. Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, , Acinetobacter baumannii clinical isolates. Antimicrob. Agents Chemother. 48, 1055-1057 (2004).
45. Traub, W. H., Haberle, R., Bauer, D. Characterization of two clinical, multipledrug-resistant isolates of Enterobacter cloacae. Chemotherapy 30, 308-321 (1984).
46. Stefanovic, O. D., Stanojevic, D. D., Comic, L. R. Synergistic antibacterial activity of Salvia officinalis, Cichorium intybus extracts, antibiotics. Acta. Pol. Pharm. 69, 457-463 (2012).
47. Park, Y., et al. Synergism of Leu-Lys rich antimicrobial peptides, chloramphenicol against bacterial cells. Biochim. Biophys. Acta. 1764, 24-32 (2006).
48. Mimoz, O., et al. Cefepime, amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro, in vivo. J. Antimicrob. Chemother. 39, 363-369 (1997).